Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Baxter International (BAX)

Baxter COO Heather Knight to resign effective October 29, 2025

Neutral Impact 3 of 5 leadership Written later

Baxter International said Executive Vice President and Chief Operating Officer Heather Knight will resign effective October 29, 2025, to join a healthcare company, and she also leaves her interim role leading Medical Products and Therapies. CEO Andrew Hider will take over that interim group president role, and the company will have no COO after the transition date. The filing gives no financial figures, but the loss of a COO and the added duties for the CEO are leadership changes shareholders may want to watch.

Key points

  • Heather Knight resigns as EVP and COO, effective October 29, 2025, to join a healthcare industry company
  • Knight also steps down as interim group president of Medical Products and Therapies on the same date
  • CEO Andrew Hider will assume the interim MPT group president role
  • After October 29, 2025, Baxter will no longer have a chief operating officer

The filing

CompanyBaxter International (BAX)
Form8-K, current report
Filed with the SECOct 21, 2025, 9:00 AM ET
Accession number0001628280-25-045586

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:12 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 21, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.